Ozempic

Novo bids for recognition in the year of NASH
Novo bids for recognition in the year of NASH
EP Vantage
NASH
Novo Nordisk
Ozempic
Flag link:
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
Fierce Biotech
diabetes
insulin
Mt Sinai
Novo Nordisk
Ozempic
Rybelsus
Victoza
Eli Lilly
Trulicity
AstraZeneca
Bydureon
Flag link:
Ozempic acceleration buoys Novo Nordisk, and threatens Lilly
Ozempic acceleration buoys Novo Nordisk, and threatens Lilly
Pharmaforum
Novo Nordisk
earnings
Ozempic
Eli Lilly
diabetes
Flag link:
Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Endpoints
Novo Nordisk
Ozempic
diabetes
cardiovascular events
FDA
Flag link:
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
Motley Fool
diabetes
Eli Lilly
Merck
Novo Nordisk
GSK
Byetta
Victoza
Bydureon
Ozempic
Tanzeum
Trulicity
Rybelsus
Flag link:
EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win
EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win
Fierce Pharma
Novo Nordisk
Ozempic
JNJ
Invokana
Victoza
diabetes
EASD
Flag link:
ICER dings Novo's new oral diabetes drug
ICER dings Novo's new oral diabetes drug
Biopharma Dive
Novo Nordisk
diabetes
ICER
oral semaglutide
Eli Lilly
Boehringer Ingelheim
Jardiance
Ozempic
Flag link:
Novo Nordisk goes for broke on semaglutide heart data
Novo Nordisk goes for broke on semaglutide heart data
Biopharma Dive
Novo Nordisk
diabetes
FDA
Ozempic
oral semaglutide
Flag link:
In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
Endpoints
Novo Nordisk
Trulicity
Ozempic
Eli Lilly
diabetes
Flag link:
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
CP Wire
Anthem
Novo Nordisk
Ozempic
type 2 diabetes
Flag link:
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
Anthem
Novo Nordisk
Ozempic
type 2 diabetes
Flag link:
Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results
Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results
Endpoints
Eli Lilly
diabetes
Novo Nordisk
Ozempic
LY3298176
Trulicity
Flag link:
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Fierce Biotech
diabetes
Parkinson's Disease
GLP-1 agonist
AstraZeneca
Byetta
Bydureon
Novo Nordisk
Victoza
Ozempic
Eli Lilly
Trulicity
Peptron
Flag link:
5 Biggest Blockbuster Diabetes Drugs of the Future
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Boehringer Ingelheim
Jardiance
Tresiba
NovoRapid
Flag link:
Novo reveals more Ozempic data on change in body weight by baseline BMI
Novo reveals more Ozempic data on change in body weight by baseline BMI
Yahoo/Reuters
Novo Nordisk
diabetes
BMI
Ozempic
Eli Lilly
Trulicity
Flag link:
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Fierce Pharma
Novo Nordisk
GLP-1 agonist
diabetes
Ozempic
drug launches
Flag link:
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Drug Delivery Business News
Japan
Novo Nordisk
diabetes
type 2 diabetes
Ozempic
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Novo Nordisk secures Ozempic formulary coverage from Express Scripts
Novo Nordisk secures Ozempic formulary coverage from Express Scripts
Fierce Pharma
Novo Nordisk
Ozempic
Express Scripts
Flag link:
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Fierce Pharma
Novo Nordisk
semaglutide
Eli Lilly
Ozempic
Trulicity
Flag link:

Pages